Journal: Materials Today Bio

Article Title: An anti-inflammatory neuroenhancer mitigates amyloid-β pathology to improve Alzheimer's disease therapy

doi: 10.1016/j.mtbio.2026.102874

Figure Lengend Snippet: RB@LCP-AR diminishes neuroinflammation and restores neuronal synapses in AD mice. AD mice were intravenously injected with the indicated formulations 5 times, then the brain tissues were collected for further analysis. (A–B) The levels of inflammatory TNF-α (A) and IL-6 (B). (C–D) The levels of MDA (C) and SOD (D). (E–G) The distribution and quantitative analysis of Iba-1 (astrocytes) and GFAP (microglia) in the brain tissues. Scale bar = 400 μm. (H–J) The distribution and quantitative analysis of PSD95 (postsynaptic) and synaptophysin (presynaptic) in the brain tissues. Scale bar = 400 μm. Data are presented by mean ± SEM (n = 6). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: Next, the sections were incubated with HRP-conjugated goat anti-mouse/rabbit IgG polymer for 20 min. To detect the synaptic protein, the sections were incubated with the primary antibody against synaptophysin and PSD95, and then incubated with corresponding secondary antibodies conjugated to Alexa Fluor 488 (Santa Cruz Biotechnology, USA) or Alexa Fluor 594 (Santa Cruz Biotechnology, USA), respectively.

Techniques: Injection

Journal: Neurochemical Research

Article Title: Morin Improves Cognitive Deficits in an in Vivo Model of Vascular Dementia by Modulating the N-methyl-D-aspartate Receptor Signaling Pathways

doi: 10.1007/s11064-026-04717-7

Figure Lengend Snippet: The impact of morin on the expression of synaptic plasticity-related proteins in the hippocampus of VaD rats. a Western blots; b the protein levels of SYP; c the protein levels of PSD-95; d the expression levels of SYP ; e the expression levels of PSD-95; f the levels of glutamate. Data are presented as mean ± SD. Statistical analysis was performed by one-way ANOVA with Tukey’s post-hoc test (data met assumptions of normality and homoscedasticity)/Kruskal-Wallis with Dunn’s test (data did not meet assumptions). * indicates a significant difference from the Sham group; # indicates a significant difference 2VO group; *# indicates a significant difference from both the Sham and 2VO groups, with a p-value of less than 0.05 considered statistically significant

Article Snippet: Primary antibodies, all diluted at 1:1000, were sourced from Santa Cruz Biotechnology and included the following: PSD-95 (sc-32290, Santa Cruz Biotechnology, Inc.), SYP (sc-17750, Santa Cruz Biotechnology, Inc.), and β-actin (sc-517582, Santa Cruz Biotechnology, Inc.).

Techniques: Expressing, Western Blot

Journal: Inflammopharmacology

Article Title: Prebiotics attenuate depressive-like behavior, neuroinflammation and synaptic plasticity in Parkinson’s disease by modulating butyrate-producing gut bacteria

doi: 10.1007/s10787-026-02152-2

Figure Lengend Snippet: a Representative images of western blot bands (Left panels), and western blot quantification of b GPR109, c p-CREB, d BDNF, e SERT and f PSD-95 in the prefrontal córtex. The data were analyzed by one-way ANOVA statistical tests of variance and Tukey’s post hoc test. NS: non-signifcant; * p < 0.05; ** p < 0.01; *** p < 0.001; pooled samples of 10 mice/group; statistical analyses were performed using the values obtained in different replicates

Article Snippet: After, the membranes were blocked with 3% BSA and incubated overnight with the following antibodies diluted in blocking solution (1.5% BSA, 0.02% Tris phosphate-buffered, and 0.01% Tween): Substantia nigra and pre-frontal cortex: tyrosine hydroxylase (Merck AB152, 1:500), α-synuclein (Santa Cruz, 1:1000), IBA-1 (Wako 016-200001, 1:500), phospho-α synuclein (Abcam, ab51253), anti IL-1β (Genway GWP-BPB232, 1:1000), anti-p-NFkB (Abcam, ab97726, 1:1000), p-CREB (Cell signaling #9198, 1:1000), anti-iNOS (BD 610600, 1:1000) and BDNF (Alomone ANT-10, 1,500), PSD-95 (Alomone #APZ-009, 1:500), serotonin transporter-SERT (Alomone labs AMT004, 1:200), GPR109 (Invitrogen PA5-90,579, 1:500).

Techniques: Western Blot

Journal: Inflammopharmacology

Article Title: Prebiotics attenuate depressive-like behavior, neuroinflammation and synaptic plasticity in Parkinson’s disease by modulating butyrate-producing gut bacteria

doi: 10.1007/s10787-026-02152-2

Figure Lengend Snippet: FOS and GOS act in the intestine by increasing the relative abundance of short-chain fatty acid-producing bacteria Bacteroidaceae, Bacteroides, Alistipes sp, Lactobacillus reuteri and reducing the pro-inflammatory species such as H. hepaticus . The prebiotics also decreased α-synuclein, p-NFKB, and IL1-β, increasing occludin and GPR43 levels, thus reducing gut inflammation and permeability. In the Substantia nigra, FOS and GOS increased the expression of TH and brain neuroplasticity factors p-CREB and BDNF, in addition to reducing IBA-1, GFAP, p-NFKB, IL1-B, iNOS and α-synuclein. In the prefrontal cortex, FOS and GOS also reduced the expression of inflammatory markers p-NFKB, IL1-β, and iNOS and promoted increased neuroplasticity by expressing SERT, PSD-95, BDNF, and p-CREB. Finally, FOS and GOS also increased brain serotonin levels

Article Snippet: After, the membranes were blocked with 3% BSA and incubated overnight with the following antibodies diluted in blocking solution (1.5% BSA, 0.02% Tris phosphate-buffered, and 0.01% Tween): Substantia nigra and pre-frontal cortex: tyrosine hydroxylase (Merck AB152, 1:500), α-synuclein (Santa Cruz, 1:1000), IBA-1 (Wako 016-200001, 1:500), phospho-α synuclein (Abcam, ab51253), anti IL-1β (Genway GWP-BPB232, 1:1000), anti-p-NFkB (Abcam, ab97726, 1:1000), p-CREB (Cell signaling #9198, 1:1000), anti-iNOS (BD 610600, 1:1000) and BDNF (Alomone ANT-10, 1,500), PSD-95 (Alomone #APZ-009, 1:500), serotonin transporter-SERT (Alomone labs AMT004, 1:200), GPR109 (Invitrogen PA5-90,579, 1:500).

Techniques: Bacteria, Permeability, Expressing